Warm Autoimmune Hemolytic Anemia Clinical Trial
Official title:
A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients With Warm Autoimmune Hemolytic Anemia
This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
This is a Phase 2, non-randomized, sequential, open-label study to investigate the safety, tolerability, PK, PD, and efficacy of RVT-1401 (680 mg/weekly and 340 mg/weekly) in patients with Warm Autoimmune Hemolytic Anemia that is worsening or refractory in spite of therapy with steroids and or immunosuppressants or worsening with steroid or immunosuppressant taper. Two cohorts of participants will be enrolled in a non-randomized sequential approach. Participants will be enrolled into Cohort 1 (680 mg/weekly) first followed by Cohort 2 (340 mg/weekly). Following the initial dose at the Baseline Visit (Week 1, Day 1), study visits will occur weekly throughout the treatment period. Following the final dose at Week 12, visits will occur weekly through Week 14 and then at Week 16 and Week 20. Safety, PK, PD, and clinical assessments will be collected throughout the study. Each participant will participate in the study for up to approximately 24 weeks: up to a 4-week screening period, a 12-week treatment period, and an 8-week follow up period. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05786573 -
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
|
Phase 3 | |
Withdrawn |
NCT03965624 -
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
|
Phase 2 | |
Recruiting |
NCT05922839 -
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
|
Phase 2 | |
Completed |
NCT01181154 -
Rituximab in Auto-Immune Hemolytic Anemia
|
Phase 3 | |
Recruiting |
NCT05925023 -
Sirolimus in the Treatment of Refractory/Relapsed wAIHA
|
Phase 2 | |
Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04256148 -
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
Terminated |
NCT03075878 -
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04956276 -
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 | |
Recruiting |
NCT04119050 -
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
|
Phase 2/Phase 3 | |
Temporarily not available |
NCT05221619 -
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
|